Featured Press Releases

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Orthofix Receives FDA 510(k) Clearance for Rodeo™ Telescopic Nail

Akebia

Akebia's Vafseo® (vadadustat) Tablets FDA Approved for Anemia Treatment in Dialysis Patients

  • 28 Mar 2024

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better...

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer's amyloid plaques

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

  • Octapharma
  • 08 Jan 2026
Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

  • Arkbio
  • 08 Jan 2026
Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

  • Novotech
  • 08 Jan 2026
Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

  • Coya Therapeutics, Inc.
  • 08 Jan 2026
RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

  • RoslinCT and BOOST Pharma
  • 07 Jan 2026
Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

  • Orum Therapeutics
  • 05 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
January   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.